| Aged 16 or over |
Subjects of either gender who are under 16 years old |
| Able to understand study requirements and attend all follow-up visits |
Any subject, who in the opinion of the investigator is unable to fully understand the requirements of the trial, consent or is unable to return to follow-up visits in order to complete the study |
| Able to provide written consent if competent |
Subjects who do not give consent or withdraw their consent to take part in the study |
| Weight between 40–150kg with a body mass index of 20–35kg/m2
|
Subjects who have a history of keloid or hypertrophic scarring |
|
Subjects who take medication known to influence/alter the healing of skin (e.g steroids) |
|
Subjects who are receiving formal oral anticoagulant therapy (e.g warfarin) |
|
Subjects who have taken part in clinical studies or received any investigational drugs 2 months prior to day 0 |
|
Subjects who have evidence of drug abuse |
|
Subjects who have had or are known to have hepatitis B or hepatitis C infection including carriers of hepatitis B surface antigen, hepatitis B core antibodies or hepatitis C antibodies. Previous vaccination against hepatitis B or C is not excluded |
|
Subjects who have previously had a positive result to the HIV antibody test or admit to belonging to a high risk group. |
|
Subjects who become systemically unwell during the research process due to external study causes. |
|
Subjects with known allergies to antibiotics |
|
Pregnant subjects or those likely to become pregnant in the next 3 months |
|
Subjects with active skin disorders considered to adversely affect wound healing by the investigators (e.g dermatitis, psoriasis etc) |
